Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

French Prospective Real-life Evaluation of the Endopredict® Genomic Signature for HR-positive,HER2-negative Early Breast Cancer

NCT07379918 is registered in ClinicalTrials.gov with Assistance Publique - Hôpitaux de Paris as lead sponsor.

NCT NCT07379918
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07379918 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
French Prospective Real-life Evaluation of the Endopredict® Genomic Signature for HR-positive,HER2-negative Early Breast Cancer
Lead sponsor
Assistance Publique - Hôpitaux de Paris
Phase
Observational
Overall status
Recruiting
Start date
June 28, 2026
Completion date
June 28, 2031
Enrollment
1,000 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer (early breast cancer), breast cancer prognostic, breast cancer survivors, early hormone receptor-positive (hr-positive), her2-negative breast cancer